David A Oxlade

Chairman of the Board

Email: david.oxlade@transcrip-partners.com

David is a pharmaceutical professional with extensive experience in the global health care industry, having worked at senior management and Board level for 6 years in the USA and 7 years in Asia.

He spent 14 years with Boehringer Mannheim and 7 years (latterly as President) with California-based Syva, both now part of Roche. He led major innovations in health care, including a revolutionary home blood glucose monitoring for diabetics, creating the largest single diagnostic market segment and established Cellmark Diagnostics to commercialise the discovery of Prof. Alec Jeffreys, "DNA Fingerprinting".

In 1998 he became CEO of Xenova, the LSE and NASDAQ listed biotech and in 2006 became Chairman of BioAnaLab, an analytical service company subsequently acquired in 2009 by Millipore Corporation. He is Chairman of base4innovation, a company developing rapid DNA sequencing systems and a Non-Executive Director of Cobra Biomanufacturing.

David is an Honorary Fellow of Brunel University, has been a member of the Emerging Enterprise Council of EuropaBio, a member from inception of the Bioscience Leadership Council, chaired the European Working Group of the Bioscience Innovation and Growth Team (set up by UK Government under Sir David Cooksey to establish a 10 year agenda for the bioscience industry in the UK).